Отрасли
Life Science Tools
Вся аналитика по отрасли Life Science Tools — 14 материалов.
48/100
Danaher: Orders and Peers Make the Bioprocessing Recovery Underwritable, but 3-4% Core Growth at 23 Times Earnings Leaves No Margin of Safety
Danaher sells recurring bioprocessing, laboratory and diagnostic workflows through specialised operating companies run on the Danaher Business System, with Cytiva consumables, Cepheid cartridges and Beckman reagents supplying most of the profit pool. Second-quarter core growth was 3.0% while more than 100 million USD of chromatography-resin shipments moved into 2027, and goodwill and intangibles reached 74.5% of assets after the 9.8 billion USD Masimo purchase, against acquisition-inclusive ROIC near 6 to 7%. Rating Hold: peer consumables data make the bioprocessing recovery underwritable, but at 23.4 times guided adjusted EPS the price already pays for a conversion Danaher cannot schedule.
42/100
49Buffett
QIAGEN: Sticky Workflow Economics With Takeover Optionality Already in the Price
QIAGEN is a molecular diagnostics and life-science tools company that monetizes an entire lab workflow, from sample prep to assays, automation and bioinformatics, selling to more than 500,000 customers across five growth pillars that target about $1.61 billion of 2026 sales. The recurring consumables model is genuinely sticky, but core organic growth still needs repair while the stock carries takeover optionality after Reuters reported KKR and strategic interest. Rating Hold: at $41.51 the shares sit inside the acceptable-hold band of $39-53, above the ideal buy zone of $30-32, so buyers are paying for both a standalone repair and a deal premium that may not arrive.
45/100
Bio-Rad Laboratories: A Company in Transition, Priced Without a Margin of Safety
Bio-Rad is a diversified life-science tools and clinical-diagnostics supplier whose core operations generated 2.58 billion USD of 2025 sales, complicated by an unusually large Sartorius AG stake that dominates its GAAP earnings. Q1 2026 brought a 527.1 million USD net loss driven by a 727.7 million USD fair-value drop on the Sartorius stake, even as the operating business still produced 108.1 million USD of operating cash flow, and management cut full-year currency-neutral revenue guidance to a range of -3.0% to +0.5%. Rating Hold: durable niche assets and real asset backing, but at 297.09 USD the price already assumes the 2026 slowdown is manageable and leaves no margin of safety.
49/100
Merck KGaA: диверсифицированная научная платформа в переходной фазе
Merck KGaA, Дармштадт, — немецкая научно-технологическая группа под семейным контролем, чьи продажи 2025 года в размере €21.1 миллиардов формируются тремя очень разными двигателями: Healthcare с патентной уязвимостью, качественной франшизой инструментов Life Science и бизнесом Electronics в материалах для полупроводников. В 2026 году акция остается полем перетягивания каната: известный патентный обрыв Mavenclad в США тянет Healthcare вниз, тогда как Process Solutions растет органически почти на 10%, а Electronics опирается на спрос ИИ на передовые техпроцессы; после майского отскока до €133.05 акции торгуются около 15.9 раза EPS pre 2025 года и дают 3.5% доходности свободного денежного потока. Рейтинг Держать: действительно сильные двигатели Life Science и материалов для полупроводников компенсируют Healthcare с поврежденной репутацией, но постоянный дисконт корпоративного управления KGaA и лишь справедливая оценка ограничивают потенциал роста.
51/100
Sartorius AG: качественное восстановление биопроцессного бизнеса уже учтено в цене
Sartorius AG — немецкая группа в сфере инструментов для наук о жизни, чья стоимость в основном определяется контролируемой биопроцессной франшизой Sartorius Stedim Biotech, тогда как ликвидной биржевой линией остаются неголосующие привилегированные акции SRT3. После пандемического бума и провала из-за сокращения запасов продажи в 2025 году восстановились на 7.6% примерно до EUR 3.54 миллиардов, базовая маржа EBITDA вернулась к 29.7%, а левередж снизился с 3.96x до 3.55x, однако около EUR 3.74 миллиардов чистого долга и все еще премиальная оценка на уровне 18x trailing EBITDA оставляют небольшой запас прочности. Рейтинг Держать: франшиза и восстановление реальны, но рынок уже видит нормализацию, а текущая цена EUR 217.10 находится выше идеальной зоны покупки отчета.
42/100
Углубленное исследование 10x Genomics
10x Genomics — компания платформ single-cell и пространственной омики, чья установленная база приборов стимулирует повторные покупки высокомаржинальных расходных материалов; на них уже долго приходится около 84%–86% выручки. По мере замедления Chromium следующий переход роста зависит от Atera, запущенной в апреле 2026, но компания всё ещё убыточна, а около 40%–50% выручки зависит от академического и государственного финансирования. Рейтинг исследования: Держать; при текущей цене USD 28.84 акция торгуется примерно по 5.1x форвардной EV/Sales, что выглядит разумно, но без запаса прочности.
41/100
Bruker Zen Horizon Research: A Hidden Champion in Scientific Instruments, but Organic Growth Is Receding and Valuation Has Priced In the Recovery
Bruker is a hidden global champion in high-end scientific analytical instruments, with a near-oligopoly position in NMR. Organic growth has turned negative for consecutive periods, reported growth is being held up by acquisitions and FX, GAAP earnings have swung to a loss, and the profit recovery depends heavily on cost execution after a roughly 70% one-month surge left the current price of $59.97 above the average sell-side target by 16% and forward PE at about 27-28x near the top of peers. Research rating Watch: a high-quality moat business that needs either a confirmed organic inflection or a pullback toward roughly $48 to restore margin of safety.
27/100
Bio-Techne Corporation: A Deep Value Investing Study
A high-quality life-science tools company trading at a rich price. At $51.68 the stock carries a trailing P/E of roughly 74.9x while three-year revenue has compounded at only 3.3%, so the margin of safety is thin. Rating Watch: ideal entry sits at $28-35, with the roughly $1 billion Wilson Wolf follow-on acquisition as the key risk to monitor.
43/100
Revvity In-Depth Value Investment Research
Revvity is a life sciences and diagnostics tools company with understandable businesses and acceptable cash generation. The core thesis is that its recurring revenue mix and focused portfolio are attractive, but its moat and capital returns are not strong enough to offset low-single-digit GAAP ROIC, $6.6 billion of goodwill, and a share price already near the low end of the optimistic case. Research rating Watch: a quality business with insufficient margin of safety at the current price, with a fair buy range of $50 to $65.
45/100
90Buffett
Mettler-Toledo International Inc.: A Value Investing Deep Dive
A global leader in precision instruments and services with excellent quality, but at roughly $1,161 the stock trades at about 27x P/E and about 28x conservative owner earnings, already close to the optimistic scenario, so the rating is Watch; the ideal buy range is $800-950; the main risks are competition in China and emerging markets, tariff erosion of gross margin, and buybacks at high valuations.
46/100
Long-Term Research on Waters' Laboratory Analytics and Diagnostic Tools
Waters sells liquid chromatography, mass spectrometry, thermal analysis, software, consumables, and services, and after acquiring BD Biosciences it has become a life-sciences and diagnostics platform. At $342, the stock is already close to the optimistic valuation band, while the ideal buy range is $200-240. Rating Watch: a high-quality business, but current pricing leaves too little margin of safety before integration and cash-flow proof improve.
48/100
Danaher Research from a Long-Term Owner's Perspective
Danaher is a platform spanning bioprocessing, life sciences, and diagnostics, with 2025 revenue of $24.668 billion, free cash flow of roughly $5.29 billion, and recurring revenue at 82%. At the current share price of $172, the stock trades at about 23x FCF, which places it in a fair-value band without enough margin of safety. Rating Watch: a durable compounder worth studying and holding, but better approached after a wider discount emerges.
47/100
69Buffett
Thermo Fisher: A Long-Term Owner's Perspective
Thermo Fisher Scientific is a full-stack scientific infrastructure platform spanning instruments, consumables, services, CRO, and CDMO capabilities. At $448, with a static P/E of 24.6x and $65.2 billion of goodwill and acquisition-related intangibles, long-term returns depend heavily on acquisition quality and execution. Rating Watch: a high-quality business, but the current price does not offer a clearly sufficient margin of safety.
44/100
83Buffett
Agilent Technologies: A Study from a Long-Term Business Owner's Perspective
A high-quality laboratory tools and services company whose CrossLab services/consumables franchise is highly sticky, with solid cash flow and low debt. At the current $113.78, mid-single-digit growth is already fully priced in and the margin of safety is insufficient; rating Watch, with an ideal buy zone of $70-85.